Combination therapy

Details Combination therapy Combination therapy

A - Human Necessities

61

K

A61K 45/06 (2006.01) A61K 31/4745 (2006.01) A61K 31/4965 (2006.01) A61K 31/517 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2610628

The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of AZD2171 in combination with 5-FU, CPT-11 or 5-FU and CPT-11; to a pharmaceutical composition comprising AZD2171 and 5-FU, CPT-11 or 5-FU and CPT-11; to a combination product comprising AZD2171 and 5-FU, CPT-11 or 5-FU and CPT-11 for use in a method of treatment of a human or animal body by therapy; to a kit comprising AZD2171 and 5-FU, CPT-11 or 5-FU and CPT-11; to the use of AZD2171 and 5-FU, CPT-11 or 5-FU and CPT-11 in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.

L'invention concerne une méthode visant à produire un effet antiangiogénique et/ou de réduction de la perméabilité vasculaire chez un animal à sang chaud, tel qu'un humain, facultativement traité au moyen d'un rayonnement ionisant. L'invention concerne en particulier une méthode de traitement du cancer, notamment un cancer impliquant une tumeur solide. Cette méthode consiste à administrer AZD2171, associé à 5-FU, CPT-11 ou 5-FU et CPT-11. L'invention concerne également une composition pharmaceutique contenant AZD2171 et 5-FU, CPT-11 ou 5-FU et CPT-11 ; un produit d'association contenant AZD2171 et 5-FU, CPT-11 ou 5-FU et CPT-11 pouvant être utilisé dans une méthode de traitement destinée à un humain ou à un animal ; un kit contenant AZD2171 et 5-FU, CPT-11 ou 5-FU et CPT-11 ; ainsi que l'utilisation de AZD2171 et 5-FU, CPT-11 ou 5-FU et CPT-11 dans la fabrication d'un médicament pouvant être utilisé pour obtenir un effet antiangiogénique et/ou de réduction de la perméabilité vasculaire chez un animal à sang chaud, tel qu'un humain, facultativement traité au moyen d'un rayonnement ionisant.

Affiliated with

Also associated with

Rating

Combination therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1537731